AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00206245
- Locations
- 🇬🇧
Research Site, Woking, United Kingdom
🇸🇪Research Siteq, Östersund, Sweden
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 454
- Registration Number
- NCT00206128
- Locations
- 🇪🇸
Research Site, Villamartin, Spain
🇱🇹Research Sitte, Vilnius, Lithuania
🇩🇪Research Center, Aachen, Nordrhein-Westfalen, Germany
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1098
- Registration Number
- NCT00206102
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
Seroquel in Bipolar Depression Versus Lithium
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 672
- Registration Number
- NCT00206141
- Locations
- 🇺🇦
Research Site, Vinnitsa, Ukraine
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 535
- Registration Number
- NCT00206115
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00206050
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00206024
- Locations
- 🇵🇷
Research Site, Ponce, Puerto Rico
Long Term Open Follow-up With H376/95 vs. Warfarin
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT00206063
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3300
- Registration Number
- NCT00206089
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 477
- Registration Number
- NCT00206219
- Locations
- 🇬🇧
Research Site, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath